Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
14 August 2023Website:
http://mirapharmaceuticals.comNext earnings report:
13 September 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:16:40 GMTDividend
Analysts recommendations
Institutional Ownership
MIRA Latest News
New preclinical studies suggest that, unlike traditional ketamine, MIRA's oral ketamine analog Ketamir-2 does not induce hyper-locomotor activity, indicative of psychotic symptoms, offering the potential for safer mental health treatments MIAMI , June 24, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a leading pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir's potential to provide therapeutic benefits without inducing schizophrenia-like behavior or hyper-locomotor activity.
The company announced that it achieved positive preclinical study results for Ketamir-2, its Novel Oral ketamine Analog.
Investigative studies are underway testing Ketamir-2 as the potential first at home ketamine analog treatment for PTSD, depression, and neuropathic pain, including cancer pain MIAMI , May 20, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications. Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2 MIRA continues to advance studies of Ketamir-2 in animal studies while improving manufacturing optimization as the company prepares for human testing in 2025.
Mira Pharmaceuticals (NASDAQ: MIRA ) stock is rising on Friday after it provided investors with an interesting preclinical trial update. The company has been investigating its preclinical studies of MIRA1a.
Cannabis-focused Mira Pharmaceuticals Inc. increased the size of its initial public offering to 1.2 million shares and set the offering price at $7 a share, according to a filing late Friday. Mira earlier this month had said it would offer 1 million shares at between $6 to $8 a share.
What type of business is MIRA Pharmaceuticals?
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
What sector is MIRA Pharmaceuticals in?
MIRA Pharmaceuticals is in the Healthcare sector
What industry is MIRA Pharmaceuticals in?
MIRA Pharmaceuticals is in the Drug Manufacturers - General industry
What country is MIRA Pharmaceuticals from?
MIRA Pharmaceuticals is headquartered in United States
When did MIRA Pharmaceuticals go public?
MIRA Pharmaceuticals initial public offering (IPO) was on 14 August 2023
What is MIRA Pharmaceuticals website?
https://mirapharmaceuticals.com
Is MIRA Pharmaceuticals in the S&P 500?
No, MIRA Pharmaceuticals is not included in the S&P 500 index
Is MIRA Pharmaceuticals in the NASDAQ 100?
No, MIRA Pharmaceuticals is not included in the NASDAQ 100 index
Is MIRA Pharmaceuticals in the Dow Jones?
No, MIRA Pharmaceuticals is not included in the Dow Jones index
When does MIRA Pharmaceuticals report earnings?
The next expected earnings date for MIRA Pharmaceuticals is 13 September 2024